What's Going On With Cancer-Focused Tempest Therapeutics Stock On Thursday?
Portfolio Pulse from Vandana Singh
Tempest Therapeutics Inc (NASDAQ:TPST) shares are trading lower despite announcing positive data from their Phase 1b/2 clinical study on amezalpat2 (TPST-1120). The drug showed a six-month improvement in median overall survival for patients with unresectable or metastatic hepatocellular carcinoma (HCC) when combined with atezolizumab and bevacizumab. Despite the positive clinical data, TPST shares are down 16.5% at $2.38.
June 20, 2024 | 1:43 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Tempest Therapeutics announced positive data from their Phase 1b/2 clinical study on amezalpat2 (TPST-1120), showing a six-month improvement in median overall survival for HCC patients. Despite this, TPST shares are down 16.5%.
Despite the positive clinical data, the significant drop in TPST's share price suggests that investors may have had higher expectations or concerns about other aspects of the company's performance or future prospects.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100